Azido-PEG3-Val-Cit-PAB-PNP
Code | Size | Price |
---|
TAR-T14436-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T14436-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker employed for synthesizing antibody-drug conjugates (ADCs)[1]. It also serves as a PEG-based PROTAC linker for the synthesis of PROTACs[2].
CAS:
2055047-18-0
Formula:
C34H47N9O12
Molecular Weight:
773.801
Purity:
0.98
SMILES:
CC(C)[C@H](NC(=O)CCOCCOCCOCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC(=O)Oc2ccc(cc2)N(=O)=O)cc1 |@@:1|
References
Dan N, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals (Basel). 2018 Apr 9;11(2). pii: E32.
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.